Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer

	Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer
刊名	CHINESE JOURNAL OF CANCER RESEARCH
	2018
卷号	30
关键词	PHASE-I POSTMENOPAUSAL WOMEN HDAC INHIBITOR MULTICENTER ENTINOSTAT TAMOXIFEN CS055/HBI-8000 RESISTANCE LETROZOLE TRIAL Advanced breast cancer hormone receptor-positive chidamide exemestane
ISSN号	1000-9604
其他题名	Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer
英文摘要	Objective: The recurrence or progression under endocrine therapy in hormone receptor-positive (HR+) advanced breast cancer (ABC) remained a critical clinical challenge. Chidamide is an oral subtype-selective histone deacetylase (HDAC) inhibitor with multiple functions in tumor growth inhibition and microenvironment modulation via epigenetic reprogramming. The purpose of this study was to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of chidamide in combination with exemestane in HR+ ABC patients.
资助项目	[Chinese National Major Project for New Drug Innovation] ; [Shenzhen municipal science and technology project]
语种	英语
CSCD记录号	CSCD:6404157
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/46890]
专题	中国科学院合肥物质科学研究院
推荐引用方式 GB/T 7714	. Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer[J]. CHINESE JOURNAL OF CANCER RESEARCH,2018,30.
APA	(2018).Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.CHINESE JOURNAL OF CANCER RESEARCH,30.
MLA	"Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer".CHINESE JOURNAL OF CANCER RESEARCH 30(2018).